Phillips-Medisize, a Molex company, announced expansion of its current Global Innovation and Development (GID) site in Struer, Denmark, earlier this month, with a dedicated Manufacturing Development and Clinical build unit scheduled to open in Q2 2020.
via Shutterstock
Phillips-Medisize increases European manufacturing presence
Phillips-Medisize provides a wide range of custom drug delivery devices, connected health solutions and end-to-end manufacturing services worldwide.
The Phillips-Medisize manufacturing facility will be equipped to serve clients with agile set up for cleanroom assembly and moulding (e.g. for clinical trials).
Approximately 500 square metres of floor space from the existing building will be repurposed for the cleanroom. The facility is designed to support late stage development of medium- and high-volume products and processes, under GMP and using state-of-the-art equipment.
John Horgan, Vice President, Global Sales and Marketing of Phillips-Medisize, said: “This expansion accelerates the manufacture of innovative, compliant and best-in-class products while reducing time to market and lowering launch risk for drug delivery device customers. Furthermore, it strengthens our client focus in Scandinavia by complementing the activities of our existing GID in Struer and our newest GID in Copenhagen.”
Phillips-Medisize further added to its European presence by opening a Global Innovation and Development centre in the Danish capital in November, adding to its UK-based centre in Cambridge.
The company’s increased focus on healthcare innovation in Europe and investment in hiring demonstrates its commitment to helping customers develop more intelligent drug delivery and connected health solutions that address patient needs.
